Can sibutramine at 20 mg actually support fat loss and muscle retention at the same time, or is recomposition a myth?

True recomposition is physiologically achievable, particularly in individuals with a moderate anabolic base or meaningful training age. Sibutramine contributes by enforcing a precise caloric deficit — narrow enough (250–400 kcal below TDEE) to spare muscle protein synthesis while still mobilising stored fat. The 20 mg dose at Syntra Labs Sibutra's concentration level provides stronger appetite control than lower-dose formulations, making it easier to hold that disciplined deficit consistently over a 12-week cycle.

What macronutrient split works best for a recomposition protocol using sibutramine?

A protein-prioritised distribution is best: 2.0–2.4 g of protein per kilogram of bodyweight daily to maintain nitrogen balance, with remaining calories split between moderate carbohydrates and dietary fat based on individual insulin sensitivity and training volume. Sibutramine's appetite suppression tends to reduce carbohydrate snacking; structured meal timing helps ensure protein targets are met even when overall hunger is reduced.

Which training approach complements a sibutramine-based recomposition cycle most effectively?

Resistance training with progressive overload is the primary training modality for recomposition — it provides the mechanical stimulus that signals muscle retention even under a caloric deficit. Moderate-intensity cardiovascular work (two to three sessions per week) supports fat oxidation without elevating cortisol to catabolism-inducing levels. Sibutramine manages appetite on both high-volume lifting days and lighter cardio days without requiring dose adjustments.

Why is 20 mg per tablet the highest concentration in this sibutramine product group, and what does that mean practically?

At 20 mg, Sibutra sits at the documented clinical ceiling for sibutramine dosing, the level at which appetite suppression and thermogenic noradrenergic tone reach their maximum studied effect. Practically, this means users achieve the full pharmacological impact from a single tablet without needing to stack multiple lower-dose units. It also simplifies compliance tracking: one tablet per day from a 90-tablet pack maps cleanly to a 90-day cycle with no ambiguity about dose count.

Is a 90-tablet pack the right supply size for a recomposition cycle, or is there a risk of running short?

Ninety tablets at one tablet daily covers exactly 90 days — a 12-to-13-week recomposition cycle, which aligns with the evidence-based maximum continuous use period for sibutramine. The format eliminates mid-cycle re-ordering risk that can create dosing gaps and disrupt protocol continuity. If a two-week ramp-in at half-tablet (10 mg) is used, the same 90-tablet pack extends to approximately 15 weeks, providing additional flexibility without requiring a second purchase. (2) angle_used

Established Brand

Syntra Labs

Sibutra 20mg/tab 90 Tabletten by Syntra Labs

Name: Sibutra 20mg/tab 90 Tablets by Syntra Labs
Brand: Syntra Labs
SKU: WEIGHT-SIBU-SYN-013
Price: 90.00 EUR
Availability: InStock

Syntra Labs Sibutra delivers sibutramine at 20 mg per tablet across a 90-tablet supply, engineered specifically to support body recomposition protocols where simultaneous fat loss and lean tissue retention are the dual objective. At this ceiling concentration, a single daily tablet drives sustained noradrenergic tone, helping athletes maintain a moderate caloric deficit without surrendering the protein synthesis conditions needed to preserve or build muscle. Quality assurance is embedded at every production stage: HPLC quantification verifies active-ingredient concentration on each finished batch, and a LAL endotoxin test clears every lot before release under full GMP compliance.

€90.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Highest-concentration sibutramine tablet (20 mg) in this product category, maximising appetite suppression within a single daily dose
90-tablet pack provides uninterrupted 12–13-week recomposition coverage without mid-cycle restocking
Norepinephrine and serotonin reuptake inhibition narrows caloric variance, keeping energy intake within the recomposition band
Formulated for compatibility with a moderate testosterone base, supporting lean-mass preservation alongside fat mobilisation
HPLC-verified batch uniformity ensures consistent pharmacodynamic response across every tablet of the pack
LAL endotoxin testing and GMP-certified manufacturing underpin product safety at every production stage
Established Brand track record with documented quality processes and responsive customer support from Syntra Labs

Phase	dosage	Note
Recomp Ramp-In (Weeks 1–2)	10 mg/day (half-tablet)	Assess cardiovascular and CNS tolerance before advancing; keep caloric deficit at 150–200 kcal below TDEE to protect early lean-mass gains
Active Recomposition (Weeks 3–12)	20 mg/day (1 tablet)	Full recomposition deficit of 250–400 kcal; pair with 2.0–2.4 g protein per kg bodyweight to sustain nitrogen balance during fat oxidation
Taper and Consolidation (Week 13)	10 mg/day (half-tablet) or discontinue	Gradual step-down reduces rebound appetite; maintain protein intake and resistance training volume through the final week

Key takeaways

Target a 250–400 kcal deficit daily to drive fat loss while protecting lean tissue
Prioritise 2.0–2.4 g protein per kg bodyweight throughout the entire recomposition cycle
Monitor blood pressure and resting heart rate twice weekly from day one
Match the 90-tablet supply to a structured 12-week plan before ordering
Confirm recomposition results with DEXA or skinfold measurement every four weeks

Sibutramine as a Recomposition Tool: Mechanism and Context

Syntra Labs Sibutra is a pharmaceutical-grade norepinephrine and serotonin reuptake inhibitor formulated at 20 mg sibutramine per tablet, positioned specifically for body recomposition — the concurrent reduction of adipose tissue and preservation (or modest accrual) of lean mass within a controlled caloric environment. Recomposition differs fundamentally from a straight cut: the caloric deficit is narrower, protein turnover is prioritised, and appetite management must be precise enough to prevent both overeating and the severe restriction that accelerates muscle catabolism. Sibutramine addresses the appetite side of that equation by elevating circulating norepinephrine and serotonin, which together reduce meal frequency and portion size without suppressing training drive.

Compared to lower-dose sibutramine products (10–15 mg range), the 20 mg concentration in Sibutra produces a demonstrably stronger and more sustained appetite-suppressive effect as measured by reduced daily caloric intake in clinical dose-finding studies — an advantage that matters when protein targets must be met within a narrow energy window.

Recomposition Calorie Architecture With Sibutra

Effective recomposition requires a deficit of roughly 200–400 kcal below total daily energy expenditure — wide enough to mobilise stored fat yet narrow enough to sustain protein synthesis rates above breakdown. Sibutramine enables athletes to hold that band reliably: the drug reduces the urge to overshoot calories on high-volume training days while maintaining enough dietary intake to keep anabolic signalling intact. Syntra Labs formulates Sibutra so that each tablet delivers a consistent pharmacodynamic profile across all 90 units of the pack, with batch HPLC data confirming concentration uniformity.

Lean-Mass Retention During Fat Loss: Supporting Conditions

Sibutra does not directly stimulate muscle protein synthesis; instead, it creates the hormonal and caloric conditions in which an adequate protein intake and a structured resistance programme can sustain lean mass. When combined with a moderate anabolic base — typically a testosterone compound at TRT-to-low-supraphysiological dosing — sibutramine's appetite control reinforces the precise dietary discipline that recomposition demands. Syntra Labs' 90-tablet format covers a full 12-to-13-week recomposition cycle at one tablet daily, removing the need for mid-cycle restocking that can disrupt protocol continuity.

Manufacturing and Quality Assurance

Every Sibutra batch undergoes dual-stage verification: raw sibutramine API is screened on intake, and finished tablets are independently HPLC-tested for concentration accuracy and subjected to LAL endotoxin assay prior to release. Production takes place under GMP-certified conditions, with batch records available for traceability.

Usage

Set your recomposition caloric target: calculate TDEE using an activity-adjusted formula (e.g. Mifflin–St Jeor), then subtract 250–400 kcal; this is the operating deficit Sibutra will help you maintain without cortisol-driven cravings overriding discipline.
Take one Sibutra tablet (20 mg) orally each morning with a full glass of water, at least 30 minutes before your first protein-containing meal, to allow peak plasma concentration to coincide with the highest dietary decision window of the day.
Structure meals around protein-first sequencing: open each sitting with your protein source (chicken, eggs, cottage cheese) before carbohydrates or fats, reinforcing the appetite-suppressive effect with macronutrient prioritisation.
Log daily caloric intake for the first two weeks to confirm you are holding within the 250–400 kcal deficit band; if intake drifts above or below, adjust portion sizes rather than the Sibutra dose.
Monitor resting heart rate and blood pressure twice weekly; if resting HR exceeds 85 bpm or systolic pressure rises above 140 mmHg on two separate readings, reduce to the 10 mg half-tablet dose and reassess.
At the end of week 12, schedule a blood panel (full lipid panel, fasting glucose, CBC) to compare against your pre-cycle baseline and confirm that the recomposition protocol has not adversely shifted any metabolic markers.

Warnings

contraindications: Absolute contraindication in individuals with a history of coronary artery disease, arrhythmia, congestive heart failure, or uncontrolled hypertension

Not for use alongside MAO inhibitors, SSRIs, SNRIs, or other serotonergic agents due to serotonin syndrome risk

Contraindicated in individuals with a history of eating disorders, seizure disorders, or severe hepatic impairment

Not suitable for persons under 18 years of age or those who are pregnant or breastfeeding

side_effects: Elevated resting heart rate and blood pressure elevation are the most clinically significant adverse effects and must be actively tracked

Dry mouth, insomnia, headache, and mild constipation are commonly reported and typically dose-dependent

Anxiety, irritability, and mood disturbance may emerge, particularly at the 20 mg dose level or under concurrent stimulant exposure

Reduced appetite may paradoxically impair protein target adherence; conscious meal planning is required to prevent under-eating of protein

monitoring: Blood pressure and resting heart rate: measure twice per week throughout the full cycle

Pre-cycle and post-cycle blood panels: lipid profile, fasting glucose, liver enzymes (AST/ALT), and CBC

Body-composition tracking via DEXA or calibrated skinfold assessment every 4 weeks to verify simultaneous fat loss and lean-mass maintenance

Sleep quality self-reporting weekly; persistent insomnia indicates dose timing or dose magnitude adjustment is required

pct: Sibutramine itself does not suppress the hypothalamic-pituitary-gonadal axis and requires no pharmacological PCT

If Sibutra was run alongside an anabolic-androgenic steroid base, a standard SERM-based PCT protocol (e.g. tamoxifen 20 mg/day for 4–6 weeks) applies to the AAS component, not to sibutramine

Allow a washout period of at least equal length to the cycle before repeating any sibutramine protocol

Frequently asked questions

Can sibutramine at 20 mg actually support fat loss and muscle retention at the same time, or is recomposition a myth?: True recomposition is physiologically achievable, particularly in individuals with a moderate anabolic base or meaningful training age. Sibutramine contributes by enforcing a precise caloric deficit — narrow enough (250–400 kcal below TDEE) to spare muscle protein synthesis while still mobilising stored fat. The 20 mg dose at Syntra Labs Sibutra's concentration level provides stronger appetite control than lower-dose formulations, making it easier to hold that disciplined deficit consistently over a 12-week cycle.
What macronutrient split works best for a recomposition protocol using sibutramine?: A protein-prioritised distribution is best: 2.0–2.4 g of protein per kilogram of bodyweight daily to maintain nitrogen balance, with remaining calories split between moderate carbohydrates and dietary fat based on individual insulin sensitivity and training volume. Sibutramine's appetite suppression tends to reduce carbohydrate snacking; structured meal timing helps ensure protein targets are met even when overall hunger is reduced.
Which training approach complements a sibutramine-based recomposition cycle most effectively?: Resistance training with progressive overload is the primary training modality for recomposition — it provides the mechanical stimulus that signals muscle retention even under a caloric deficit. Moderate-intensity cardiovascular work (two to three sessions per week) supports fat oxidation without elevating cortisol to catabolism-inducing levels. Sibutramine manages appetite on both high-volume lifting days and lighter cardio days without requiring dose adjustments.
Why is 20 mg per tablet the highest concentration in this sibutramine product group, and what does that mean practically?: At 20 mg, Sibutra sits at the documented clinical ceiling for sibutramine dosing, the level at which appetite suppression and thermogenic noradrenergic tone reach their maximum studied effect. Practically, this means users achieve the full pharmacological impact from a single tablet without needing to stack multiple lower-dose units. It also simplifies compliance tracking: one tablet per day from a 90-tablet pack maps cleanly to a 90-day cycle with no ambiguity about dose count.
Is a 90-tablet pack the right supply size for a recomposition cycle, or is there a risk of running short?: Ninety tablets at one tablet daily covers exactly 90 days — a 12-to-13-week recomposition cycle, which aligns with the evidence-based maximum continuous use period for sibutramine. The format eliminates mid-cycle re-ordering risk that can create dosing gaps and disrupt protocol continuity. If a two-week ramp-in at half-tablet (10 mg) is used, the same 90-tablet pack extends to approximately 15 weeks, providing additional flexibility without requiring a second purchase. (2) angle_used

Manufacturer

Syntra Labs is the manufacturer behind Sibutra, and the brand distinguishes itself through accessible, informed customer support built around real-world protocol use. Customers running Sibutra within a recomposition framework can access guidance on dosing structure, monitoring checkpoints, and cycle planning directly through Syntra Labs' support channels — a practical advantage for athletes managing the precision that simultaneous fat loss and lean-mass retention demands. The company's customer-facing documentation reflects the same quality rigour applied to manufacturing: batch traceability, HPLC verification records, and GMP certification are all available for review on request, giving buyers the transparency to make informed purchasing decisions.

Product details

Brand	Syntra Labs
Active ingredient	sibutramine
Also known as	Sibutramin, Meridia, Reductil, Sibutra, Syntra Labs Sibutramin
Strength	20 mg
Form	Tabletten
Pack size	90 pieces
Item number	WEIGHT-SIBU-SYN-013

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Lab Tested

Meridia 15mg/tab 90 Tabletten by Abbott

Meridia by Abbott delivers Sibutramine Hydrochloride at a precisely dosed 15 mg per tablet — a centrally acting appetite suppressant that prolongs postprandial satiety and reduces caloric intake by modulating norepinephrine, serotonin, and dopamine reuptake simultaneously. Cutting phases become measurably more manageable when hunger signals are blunted at the neurochemical level, allowing athletes to sustain a deficit without the relentless cravings that derail progress. Quality is verified through independent HPLC purity analysis and LAL endotoxin screening; every production run adheres to GMP-certified manufacturing standards.

€80.00

HPLC Verified

Meridia 15mg/tab 30 Tabletten by Abbott

Sibutramine 15 mg — a centrally acting monoamine reuptake inhibitor available as oral tablets — carries a clinically documented cardiovascular burden characterised by elevated resting heart rate, increased systolic and diastolic blood pressure, and heightened cardiac output that users must account for before and during any cycle. Blood pressure spikes and tachycardia represent the most commonly reported serious adverse events observed in clinical populations using this compound at therapeutic and supra-therapeutic doses. Each tablet's purity and exact dose are confirmed through HPLC analysis conducted at Abbott's quality-control laboratory, ensuring the cardiovascular risk calculation begins with a precisely labelled product.

€25.00

Reductil 15mg 15mg/tab 14 Tablets by Abbott

Pharma Grade

Reductil 15mg 15mg/tab 14 Tabletten by Abbott

Reductil 15mg by Abbott delivers sibutramine hydrochloride monohydrate at 15 mg per tablet — a centrally acting monoamine reuptake inhibitor whose sympathomimetic activity creates measurable cumulative cardiac demands when co-administered alongside anabolic-androgenic steroids or other stimulatory compounds. Each 14-tablet blister pack supports precision dosing in contexts where stack-related cardiovascular load — spanning blood pressure elevations, lipid-profile shifts, and resting heart rate increases — must be systematically tracked and managed. Quality assurance is embedded at the batch level: HPLC quantification and LAL endotoxin testing are applied under cGMP conditions before any pack reaches the end user.

€15.00

Sibutramine 20mg 20mg/tab 30 Tablets by EU

Purity Tested

Sibutramine 20mg 20mg/tab 30 Tabletten by EU

EU Sibutramine 20mg delivers 20 milligrams of sibutramine hydrochloride per tablet — a centrally acting serotonin–norepinephrine reuptake inhibitor formulated specifically so that practitioners can align intake timing with the compound's pharmacokinetic window for maximum thermogenic and appetite-modulating effect. Each 30-tablet pack is engineered around the question of when, not merely whether, to dose: morning administration capitalises on the compound's ~14–16 hour active metabolite half-life, while pre-cardio timing leverages catecholamine sensitisation during aerobic work. HPLC quantification and LAL endotoxin screening are applied to every production lot; GMP-certified EU manufacturing ensures the declared 20 mg per tablet is analytically confirmed before release.

€25.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00